Pascal Deschatelets - Jun 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Scientific Officer
Signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol: APLS
Transactions as of: Jun 8, 2022
Transactions value $: -$479,685
Form type: 4
Date filed: 6/9/2022, 05:23 PM
Previous filing: May 2, 2022
Next filing: Jun 22, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$32K	+12K	+1.35%	$2.67^*	904K	Jun 8, 2022	Direct	F1
transaction	APLS	Common Stock	Sale	-$529K	-12K	-1.33%	$44.09	892K	Jun 8, 2022	Direct	F1
transaction	APLS	Common Stock	Options Exercise	$17.4K	+6.5K	+0.73%	$2.67^*	898K	Jun 8, 2022	Direct	F2

Showing 1 to 3 of 3 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-12K	-3.29%	$0.00	353K	Jun 8, 2022	Common Stock	12K	$2.67	Direct	F1, F3
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-6.5K	-1.84%	$0.00	346K	Jun 8, 2022	Common Stock	6.5K	$2.67	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2	This is a scheduled exercise from 10B5-1 trading plan.
F3	This stock option was granted on 12/5/2013 and is fully vested.